Today (December 28), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security of the PRC officially announced the National Reimbursement Drug List under Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Programs (2020) ("National Reimbursement Drug List"), in which Hansoh Pharma's Ameile (Almonertinib Mesilate Tablets), Hansoh Xinfu (Flumatinib Mesylate Tablets) and Fulaimei (Polyethylene Glycol Loxenatide Injection) are included. The new inclusion of the three innovative drugs of Hansoh Pharma into the National Reimbursement Drug List is expected to improve the accessibility and affordability of domestic innovative drugs as well as the standardization of clinical treatment, benefit more patients and bring more social benefits, and is also a full affirmation of the clinical efficacy of these drugs and the innovative R&D strength of Hansoh Pharma.

3 innovative drugs

n   Ameile (Almonertinib Mesilate Tablets)

China's first independently developed third-generation EGFR-TKI innovative drug

Used to treat NSCLC and address T790M drug resistance

The world's first third-generation EGFR-TKI with a mPFS of more than 1 year (second-line use)

Included in the 2020 CSCO Guidelines for Diagnosis and Treatment of Non-small Cell Lung Cancer

n   Hansoh Xinfu (Flumatinib Mesylate Tablets)

China's first independently developed second-generation innovative drug for chronic myeloid leukemia

"Two-way optimization" in efficacy and safety

Included in the Guidelines for the Diagnosis and Treatment of Chronic Myeloid Leukemia in China (2020 Edition)

n   Fulaimei (Polyethylene Glycol Loxenatide Injection)

China's first long-acting GLP-1 class hypoglycemic drug, and the world's first PEGylated long-acting hypoglycemic drug

Clear glucose-lowering efficacy, high safety, and only one injection per week required

Hansoh Pharma has been responding proactively to the national policy and taking concrete actions to reduce the burden of national health insurance programs and fulfill its social responsibility as a Chinese pharmaceutical company. The three innovative drugs newly included in the National Reimbursement Drug List this time involve high morbidity diseases such as tumors and diabetes, are all clinically necessary, significantly efficacious, highly safe and urgently needed by patients, and after their inclusion in the National Reimbursement Drug List, are expected to reduce the economic burden of medication on patients and truly become a high-quality drug that patients can afford, so as to help improve the standardization of clinical treatment and benefit more patients. In the future, Hansoh Pharma will continue to carry out the corporate mission to "create excellence in pharmaceuticals, enhance innovation in China" and steadily accelerate the pace of R&D innovation, with a view to serving Chinese patients with more high-quality innovative drugs and further contributing to the improvement of the national health level.